Success Metrics

Completion Rate
0%(0/1)
Active Trials
4(57%)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
2
29%
Ph phase_3
2
29%
Ph not_applicable
1
14%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Terminated(1)
Other(2)

Detailed Status

Active, not recruiting2
Recruiting2
Terminated1
unknown1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 32 (28.6%)
N/A1 (14.3%)

Trials by Status

terminated114%
active_not_recruiting229%
unknown114%
recruiting229%
suspended114%

Recent Activity

Clinical Trials (7)

Drug Details

Intervention Type
PROCEDURE
Total Trials
7